

Collaborative Working Project executive summary

Project title	A Collaborative Working Agreement between Sanofi and the West of Scotland Cancer Network (WoSCAN) to review the current SACT service for multiple myeloma and explore potential delivery of appropriate SACT medications within a home setting.
Partner organisation/s	West of Scotland Cancer Network Sanofi
Project rationale	<p>Multiple myeloma is the second most common haematological malignancy and accounts for at least 2% of all cancer-related deaths. Many treatments available involve the regular utilisation of specialist hospital services. Increasing survival rates and the need for ongoing treatment are leading to increased pressure within already stretched NHS services particularly services delivering SACT.</p> <p>The West of Scotland Cancer Network (WoSCAN) realise that there are potential service changes that could be explored which would enable some of the Multiple Myeloma SACT services, currently delivered in hospital, to be delivered closer to patients' homes and potentially within patients' homes.</p> <p>The aim of the project is:</p> <ul style="list-style-type: none"> • To map out the current SACT (Systemic Anti-Cancer Treatments) service within the West of Scotland for multiple myeloma (MM) patients' data from which would be used as a baseline measure of current service delivery. • To identify and explore the potential delivery of appropriate SACT medications within a home setting, thereby releasing hospital chair time for SACT regimens requiring hospital delivery.
Project period	Q1 2025 – Q3 2025

<p>Project objectives</p>	<p>Patients:</p> <ul style="list-style-type: none"> • The feasibility of improved, timely access to SACT services in the patient's preferred location. • The possibility of improved specialist service access for treatment options requiring hospital delivery. <p>NHS:</p> <ul style="list-style-type: none"> • Achieve an improved understanding of current SACT service delivery for MM patients. • Develop insight of where the service could potentially be changed to benefit patients and improve service delivery. • The possibility of improved specialist service capacity for treatment options requiring hospital outpatient delivery. <p>Sanofi:</p> <ul style="list-style-type: none"> • Improved understanding of the pressure points and priorities associated with SACT delivery for MM patients. • Improved corporate reputation within WoSCAN. • As Sanofi produce medicines within this disease area if overall patient care is optimised there may be an increase in the usage of these products in line with national and local guidelines. <p>Resources for the project equate to approximately £10,000 (Sanofi 51% NHS 49%)</p>
<p>Contact details</p>	<p>Sanofi Andrew Moulson NHS Key Account Director GB-patientaccess@sanofi.com</p> <p>WoSCAN – NHS Greater Glasgow and Clyde Heather Wotherspoon MCN & Improvement Manager heather.wotherspoon@nhs.scot</p>